Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2016

Open Access 01-12-2015 | Letter

Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?

Authors: Patrick M. Honore, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Viola Van Gorp, Herbert D. Spapen

Published in: Critical Care | Issue 1/2016

Login to get access

Excerpt

Heparin-induced thrombocytopenia (HIT) type II is a highly morbid and potentially life-threatening condition with limited treatment options in older patients at high risk of bleeding who develop acute kidney injury (AKI). The recent study by Tardy-Poncet et al. [1] showing that argatroban may be a safe and valid therapeutic option in this patient population is therefore of utmost clinical importance. However, when discussing other alternative therapies for HIT type II, the authors did not mention recent experience with fondaparinux, a selective synthetic antithrombin-mediated inhibitor of coagulation factor Xa [2]. …
Literature
1.
Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Crit Care. 2015;19:396.PubMedPubMedCentralCrossRef
2.
Brown P, Jay R, Fox A, Oliver M. Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis—a case report and review of the literature. Hemodial Int. 2013;17:444–9.PubMedCrossRef
3.
Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother. 2006;40:1383–7.PubMedCrossRef
4.
Sharathkumar AA, Crandall C, Lin JJ, Pipe S. Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. J Pediatr Hematol Oncol. 2007;29:581–4.PubMedCrossRef
5.
Kalicki RM, Aregger F, Alberio L, Lammle B, Frey FJ, Uehlinger DE. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost. 2007;98:1200–7.PubMed
6.
Cegarra-Sanmartin V, Gonzales-Rodriguez R, Paniagua-Iglesis P, Santamaria-Ortiz A, Cueva L, Galan-Serrano J, et al. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. J Cardiothorac Vasc Anesth. 2014;28:1008–12.PubMedCrossRef
7.
Pappalardo F, Scandroglio A, Maj G, Zangrillo A, D’Angelo A. Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J Thorac Cardiovasc Surg. 2010;139:790–2.PubMedCrossRef
8.
Warkentin TE, Pai M, Sheppard I, Schulman S, Spyropoulos C. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonine-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9:2389–96.PubMedCrossRef
Metadata
Title
Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
Authors
Patrick M. Honore
Rita Jacobs
Inne Hendrickx
Elisabeth De Waele
Viola Van Gorp
Herbert D. Spapen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2016
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-016-1196-6

Other articles of this Issue 1/2016

Critical Care 1/2016 Go to the issue

Editorial

Fecal microbiota transplantation for multiple organ dysfunction syndrome

Commentary

The younger frail critically ill patient: a newly recognised phenomenon in intensive care?

Review

Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure

Research

Patient outcomes after critical illness: a systematic review of qualitative studies following hospital discharge

Research

Acute kidney injury subphenotypes based on creatinine trajectory identifies patients at increased risk of death

Commentary

Latent AKI is… still AKI: the quantification of the burden of renal dysfunction